Drug treatments for obesity

This page was started in the framework of an Eduzendium course and needs to be assessed for quality. If this is done, this {{EZnotice}} can be removed.

This page was written by a group of 4 Final Year Physiology Undergraduates at The University of Edinburgh as part of an elective we worked on (September - December 2009) called 'Appetite and Obesity'. It is the culmination of 8-10 weeks of work and is based on our studies both inside and outside the course.

Introduction

The current generation of pharmacological interventions for the treatment of obesity is ineffective. Whilst many treatments are promising in the short term; long term maintanence is a key problem that has yet to be overcome. With the ever inceasing prevalence of obesity in the developed, and now developing world, it is an integral concern to epidemiologists, policy makers and scientists looking to treat obesity.

Here we explain the basic mechanisms of action underlying the current pharmacological treatments and also the avenues of development that any future drugs may take. The field of anti-obesity and weight loss pharmacology is one that is in its infancy, and could conceivably be worth billions.

Serotonin & Noradrenaline Related Drugs

By Bruce McLintock

Sibutramine is a drug, originally used in the treatment of depression, which is now used to help obese and overweight patients lose weight, and along with Orlistat, is the only drug licensed for use in the UK. It acts within the hypothalamus by preventing reuptake of both noradrenaline and serotonin. This inhibition causes the patient increased feelings of satiety, a decreased appetite, and a corresponding reduced intake of food which results in weight loss. Certain studies have shown that sibutramine may increase thermogenesis and as such, contribute to weight loss, but there have also been other studies in which no such effects were shown, and it seems fair to say that this action seems to only contribute in, at most, a minor way to weight loss.

Endocannabinoids

One method of pharmaceutically tackling obesity is to give cannabinoid receptor type 1 (CB1 receptor) antagonists such as rimonabant. Mice genetically engineered to be deficient in CB-1 receptors have been shown to be resistant to diet induced obesity [N1] Numerous clinical trials have demonstrated weight loss in obese subjects, as well as improving the ratio of good (HDL) to bad (LDL) cholesterol.

However, a major issue in using CB1 antagonists is the incidence of psychiatric problems, in particular, depression (unfortunately several suicides occured during trials [N2]). As a result, the FDA has not approved the use of rimonabant in the United States. The European Medicines Agency (EMEA) has recommended the marketing authorisation of rimonabant be suspended across the EU, and consequently NICE has withdrawn its guidance for the use of the drug [N3].

Review: The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. http://eurheartj.oxfordjournals.org/cgi/reprint/ehn255v1.pdf [N1] Review: Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety [N2] Rimonabant for the treatment of overweight and obese patients: http://www.nice.org.uk/TA144 [N3]

Peripheral Drugs

‘Peripherally acting anti-obesity drugs’ are another class of medication aimed at causing weight loss in overweight and obese individuals. These work by reducing the calorie intake from food, or altering the metabolism of it in the gastrointestinal system (gut). There is currently only one drug of this kind that is approved for use globally - Orlistat (Xenicol) - and it works by inhibiting the enzyme lipase that breaks down fat in the gut, meaning that the fat cannot be absorbed from food, and instead it is excreted out of the body.[R3]. Studies have shown that is can reduce the amount of fat absorbed from the gut by 30%, causing a decreased calorie intake and therefore weight loss. The weight loss from taking this medication is found to be between 5-10% on average.[R2][R6]. As well as weight loss, Orlistat has been shown to improve several other cardiovascular risk-factors. Low-density lipoproteins (LDL) and triglyceride levels were shown to be reduced by 10% more than expected for the weight loss, as well as blood pressure, waist circumference and lipids being reduced.[R2][R5]. Some research also suggests that Orlistat reduces fasting glucose and HbA1c levels in type 2 diabetics by more than predicted for the weight loss, with suggested methods including increased insulin sensitivity and glucagon-like peptide-1 secretion in the small intestine. Orlistat also helps to reduce the risk of type 2 diabetes in obese subjects by 37.3%. [R2].

However, this drug does not come without some side-effects. Oily-spotting, flatulence, abdominal cramps, faecal urgency/incontinence and liquid stools are the common adverse effects of Orlistat, due to an increase of fat in the gut and stools.[R3]. These side-effects are reported to only be experienced during the early stages, “but they subside as patients learn to use the drug”.[R4]. Orlistat also prevents some absorption of fat-soluble vitamins (A,E,D,K), and so patients are recommended to take supplements.[R3]. The drug does not have any systemic side-effects as it is contained in the gut, however it does affect the absorption of acyclovir, and they shouldn’t be used at the same time. [R4].

In 2001 the NHS National Institute for Health and Clinical Excellence (NICE) issued a press release on guidance for Orlistat use, and it states that it is cost effective to the NHS.[R8]. Studies have also shown that Orlistat is a cost-effective drug in obese adults.[R2].

As well as pharmaceutical drugs that work in the periphery to cause weight loss, there are also intrinsic chemicals produced in the body (hormones) that when released cause a feeling of satisfaction and being ‘full up’. These are called satiety signals. One example is Amylin, which is a hormone secreted along with insulin from the pancreas in response to a meal, causing you to feel full, therefore regulating your meal size. An amylin analogue, Pramlintide, is currently being looked into as a potential anti-obesity therapy, with it already being used in diabetics. Another example is glucagon-like peptide-1, which is released from the gut during eating, and relays satiety information to the brain via the vagus nerve. This is not yet approved, however, for obesity treatment. Another hormone secreted in the gut, peptide YY, could also be a potential for use, along with pancreatic polypeptide (PP) – both of which decrease appetite. Small-scale trials in a peptide called Oxyntomodulin have also been promising, with larger trials waiting to be preformed. [R5].

Off Label Uses of Prescribed Medication

There are certain drugs, that are not primarily indicated for use as weight loss therapies; however they may be effective in this role. Below is a list of drugs and the evidence to support or disprove their usefulness as anti-obesity agents.

Anti-Diabetic Medication

Metformin & Acarbose

In patients with type II diabetes, there is evidence to support the use of metformin and acarbose as weight loss agents [M2]. The role of metformin in stabilising blood glucose levels has been shown to aid weight loss and also - perhaps by another mechanism - to reduce appetite [M3]. Acarbose is believed to simply slow nutrient digestion and interact with Glucagon-like Peptide-1 to aid a slight weight loss [M2].

In contrast to this, patients without type II diabetes will not benefit to the same extent [M1]. In The Diabetes Prevention Program, the weight loss achieved in a group of non-diabetic patients taking metformin was approximately half of that of a 'lifestyle modification' group. And the mean weight loss was only slightly higher than in the placebo group [M4]. Acarbose is of even less use in this context, neither helping with weight loss or with maintaining a healthy weight.

M1 - Reference: Review: Role of metformin for weight management in patients without type 2 diabetes. 2008. [Desilets A. R.]

M2 - Reference: Review: Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes? 2003. [Siraj E. S.]

M3 - Reference: Article: Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. 1998. [Lee A.]

M4 - Reference: Article: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. 2002.[Diabetes Prevention Program Research Group]

Diuretics

Diuretics, cause an increase in fluid loss (e.g. by means of hypo-absorption in the nephron), and as such have no role in weight loss by reducing body fat stores. They are abused, however as means of a 'quick-fix' pseudo-weight loss, giving the impression of a reduction in body weight whilst in reality, they are simply causing dehyrdration. They have been used for some time in the sporting world, particularly boxing, for boxers to 'make the weight' or simply to reduce likelihood of other drugs being found by urine testing [M5]. The are also used by women suffering from pre-menstrual water retention [M6].

M5 - Reference: Review: Abuse of Drugs Associated with Eating Disorders. 1992. [Bulik C.]

M6 - Reference: Review: Enhancement of athletic performance with drugs. An overview. 1991. [Wagner J]

Thyroid Hormones

One potential method of tackling obesity is the use of thyroid hormone mimetics. Thyroid hormones (T3, T4) act on the thyroid hormone receptors (THR) to elevate the body’s metabolic rate, increasing oxygen consumption leading to an increased use of fat for energy production. However the hormones also have stimulatory effects on the heart rate, causing tachycardia and dangerous arrhythmias, as well as raising the metabolism of muscle protein and promoting bone turnover. [N5]

Thyroid hormone mimetics – compounds with similar effects on the fat metabolism without causing any of the unwanted cardiac symptoms – have been developed and tested on animals. One of these named GC-1, an agonist for the thyroid hormone receptor beta 1 (THRB1) has been shown to have minimal effects on the cardiac muscle, whilst stimulating fat metabolism in rats. GC-1 has also been shown to reduce body weight in primates, though this may not specifically be fat loss.

GC-1 and KB2155 (another THRB1 agonist) have been tested in human trials, with no report of weight loss, though this could be due to insufficient doses or the minimal trial period. It remains to be seen what benefit these drugs could offer in humans, both on obesity and on other metabolic conditions. [N6]

M4 - Reference: Review: Thyroid hormones in the pathogenesis and treatment of obesity [Krotkiewski M.]

M5 - Reference: Review: New Targets for Obesity Pharmacotherapy [Aronne L. J.]

N5 - Drugs used in diseases of the thyroid; hypothyroidism. Rang & Dale Pharmacology [page 441-444]

N6 - Reference: Review: Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes [Baxter J. D.] available - http://www.nature.com/nrd/journal/v8/n4/full/nrd2830.html

Caffeine & Ephedrine

Caffeine is a stimulant belonging to the xanthine class of drugs. It is an attractive pharmacological agent for consideration in the context of helping people to lose weight, not only because of its wide global availability, social acceptability and price.

Caffeine has been shown to be effective in increasing thermogenesis in humans and reducing appetite, however as a long-term weight loss agent it is ineffective [M7]. This is believed to be because of the tolerance that develops to caffeine usage.

Ephedrine is a sympathomimetic amine, which acts as a stimulant and appetite suppressant. It has been shown to have mild efficacy as a weight loss drug and when combined synergistically with caffeine, it have been shown to be very effective for long-term weight loss [M6].

M6 - Reference: Review: The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent [Greenway et Al.]

M7 - Reference: Review: Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea [Diepvens et Al.]

Amphetamines & Cocaine

Cocaine- and Amphetamine- Regulated Transcript (CART) is a peptide produced in the hypothalamus. It plays a role in satiety, in association with leptin and neuropeptin Y (NPY); the former enhances satiety whereas the latter stimulates hunger.

CART production has been shown to decrease in obese animals with dysfunctional leptin signalling, for example in the ob/ob mouse (which cannot produce leptin) and the fa/fa rat (which is resistant to leptin). The same animal models have increased NPY in the hypothalamus, indicating that leptin plays a role in inhibiting the NPY-mediated hunger signalling; this role seems to be partially facilitated by CART, as CART administration to the brain has been shown to inhibit feeding in rats.

In summary, CART appears to stimulate satiety, and is produced in response to leptin. It also inhibits feelings of hunger, perhaps by an interaction with NPY. See diagram. Pharmaceutically exploiting its actions could be a potential method of tackling obesity. M8

M8 - Article: Paper: Hypothalamic CART is a new anorectic peptide regulated by leptin [Kristensen et Al.]